Page Menu

Hodgkin Lymphoma Clinical Trials

At Moffitt Cancer Center, Hodgkin lymphoma clinical trials are continually providing our patients with access to newer and more effective treatment options. Through these important research studies, our patients are often able to benefit from novel therapies that aren’t yet available in other settings. These options may include new approaches to bone marrow transplantation, new chemotherapy medications and biologic therapies that use the body’s immune system to fight cancer.

Clinical Trials at Moffitt Cancer Center

Each clinical trial is different, but many of Moffitt’s studies are designed for patients who haven’t achieved remission through standard treatments. Through these unique opportunities, some patients with recurrent lymphoma or failed treatment may find additional options for improving their prognoses and quality of life.

Patients who participate in Moffitt’s clinical trials can also benefit from:

  • Individualized recommendations – Moffitt’s team is here to match each patient with the research opportunities that are most appropriate for his or her unique needs.
  • National Cancer Institute-backed studies – The National Cancer Institute has named Moffitt a Comprehensive Cancer Center, and we are the only such center based in Florida. Many of our research studies are made possible through National Cancer Institute grants, and our Comprehensive Cancer Center designation speaks to our long-standing commitment to innovation, excellence and research.
  • Our translational approach – Constantly working behind the scenes to determine how Hodgkin lymphoma develops, spreads and responds to different treatments, we use everything we learn in the laboratory to directly benefit our patients. Individuals who participate in our clinical trials aren’t just expanding their own options – they’re improving the future of treatment for everyone who faces a Hodgkin lymphoma diagnosis.

A referral is not required to participate in any of our Hodgkin lymphoma clinical trials. For more information, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 19627

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19715

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19829

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20069

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20578

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20608

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20737

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release

Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20751

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21094

An Open Label, Multi-Cohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination with Chemotherapy in Patients with Advanced T-cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21096

A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21122

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21623

A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 90001

A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

Disease Site: Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20397

A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details